Breaking News Instant updates and real-time market news.

ENV

Envestnet

$69.17

-0.39 (-0.56%)

07:09
04/18/19
04/18
07:09
04/18/19
07:09

Envestnet initiated with a Buy at SunTrust

SunTrust analyst Oscar Turner initiated Envestnet with a Buy rating and a price target of $80, citing the company's "product leadership" and large total addressable market for wealth management software that allows financial advisors to spend more time on client recruitment and service. The analyst points to the company's "impressive" 5-year annualized revenue growth of about 40% and believes that the shift to fee-based advisors, along with "increased demand for unified platforms", will continue as "tailwinds" for Envestnet. Turner adds that the platform contains an "opportunity to cross-sell new solutions within its existing customer base", driving the company's long-term organic revenue growth in "at least the low double-digit range."

  • 16

    May

  • 05

    Jun

ENV Envestnet
$69.17

-0.39 (-0.56%)

03/20/19
DADA
03/20/19
DOWNGRADE
DADA
Neutral
Envestnet downgraded to Neutral from Buy at DA Davidson
03/20/19
03/20/19
DOWNGRADE
Target $67

Neutral
Envestnet downgraded to Neutral at DA Davidson on valuation
As previously reported, DA Davidson analyst Peter Heckmann downgraded Envestnet to Neutral from Buy but also raised his price target to $67 from $64, saying the rebound in shares has taken valuation on the stock to more fair levels. In spite of the increase in financial leverage, the analyst also views Envestnet's PIEtech acquisition last week positively, positioning the company as a "leader in financial planning solutions for financial advisors." Given that earnings accretion from the deal is expected to be immediate, Heckmann raises his Envestnet EPS outlook for FY19 and FY20 by 10c and 12c to $2.14 and $2.62 respectively.
03/20/19
03/20/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Monster Beverage (MNST) downgraded to Neutral from Conviction Buy at Goldman Sachs with analyst Judy Hong saying the company's U.S. sales could remain softer than expected in the near term, driving downward estimate revisions. 2. FedEx (FDX) downgraded to Neutral from Overweight at JPMorgan with analyst Brian Ossenbeck noting FedEx's outlook was lowered more than expected as legacy Express leverage to a strong airfreight market was muted and the full TNT integration remains a second half of 2020 event. 3. Rockwell Automation (ROK) downgraded to Neutral from Buy at UBS with analyst Peter Lennox-King seeing a balanced risk/reward profile given the company's "decelerating growth outlook." 4. Teradata (TDC) downgraded to Sell from Neutral at Citi with analyst Tyler Radke saying shares are up over 20% since the company preannounced a strong Q4, but the quarter benefitted from one-offs. 5. Envestnet (ENV) downgraded to Neutral from Buy at DA Davidson with analyst Peter Heckmann noting the rebound in shares has taken valuation on the stock to more fair levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/18/19
RHCO
04/18/19
INITIATION
Target $80
RHCO
Buy
Envestnet initiated with a Buy at SunTrust
SunTrust initiated Envestnet with a Buy and $80 price target.

TODAY'S FREE FLY STORIES

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

18:40
12/08/19
12/08
18:40
12/08/19
18:40
Recommendations
Agios Pharmaceuticals analyst commentary  »

Agios' initial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

18:34
12/08/19
12/08
18:34
12/08/19
18:34
Recommendations
Blueprint Medicines analyst commentary  »

Piper says 'jury…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

18:29
12/08/19
12/08
18:29
12/08/19
18:29
Recommendations
Fate Therapeutics analyst commentary  »

FT500 data validates Fate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCKT

Rocket Pharmaceuticals

$22.37

2.61 (13.21%)

18:05
12/08/19
12/08
18:05
12/08/19
18:05
Hot Stocks
Rocket says Phase 1 trial establishes feasibility of commercial Process B for FA »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

ARGX

Argenx

$147.31

-2.56 (-1.71%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

18:03
12/08/19
12/08
18:03
12/08/19
18:03
Recommendations
Argenx, Johnson & Johnson analyst commentary  »

Argenx data on…

ARGX

Argenx

$147.31

-2.56 (-1.71%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 16

    Dec

  • 21

    Jan

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

17:58
12/08/19
12/08
17:58
12/08/19
17:58
Recommendations
Bluebird Bio, Johnson & Johnson, Amgen, Bristol-Myers, Regeneron analyst commentary  »

Piper says…

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

AMGN

Amgen

$233.74

0.3 (0.13%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

REGN

Regeneron

$372.26

4.02 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

  • 21

    Jan

BGNE

BeiGene

$186.89

-2.3 (-1.22%)

17:50
12/08/19
12/08
17:50
12/08/19
17:50
Hot Stocks
BeiGene announces data from two clinical trials of Brukinsa at ASH meeting »

BeiGene announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 27

    Feb

LLY

Eli Lilly

$119.59

-0.175 (-0.15%)

16:34
12/08/19
12/08
16:34
12/08/19
16:34
Hot Stocks
Eli Lilly presents interim clinical data from LOXO-305 dose escalation trial »

Eli Lilly announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 17

    Dec

  • 30

    Jan

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

16:32
12/08/19
12/08
16:32
12/08/19
16:32
Hot Stocks
Bristol-Myers announces data from multiple liso-cel studies at ASH meeting »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

QURE

uniQure

$66.06

1.5 (2.32%)

16:26
12/08/19
12/08
16:26
12/08/19
16:26
Hot Stocks
uniQure reports 1-year follow-up data from etranacogene dezaparvovec study »

uniQure announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

FTSV

Forty Seven

$14.40

0.23 (1.62%)

15:56
12/08/19
12/08
15:56
12/08/19
15:56
Conference/Events
Forty Seven to hold an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AQST

Aquestive Therapeutics

$8.02

-0.34 (-4.07%)

15:50
12/08/19
12/08
15:50
12/08/19
15:50
Conference/Events
Aquestive Therapeutics holds analyst & investor event w/conference call hookup »

Management and Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

APRE

Aprea Therapeutics

$26.20

1.995 (8.24%)

15:23
12/08/19
12/08
15:23
12/08/19
15:23
Conference/Events
Aprea Therapeutics to hold a clinical update meeting »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

15:18
12/08/19
12/08
15:18
12/08/19
15:18
Conference/Events
Blueprint Medicines to hold an anlayst and investor event »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

IFF

International Flavors

$142.03

0.21 (0.15%)

, DD

DuPont

$63.60

1.6 (2.58%)

13:47
12/08/19
12/08
13:47
12/08/19
13:47
Periodicals
International Flavors in talks to buy DuPont nutrition unit, Bloomberg reports »

International Flavors…

IFF

International Flavors

$142.03

0.21 (0.15%)

DD

DuPont

$63.60

1.6 (2.58%)

KRYAY

Kerry Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHWRF

China Tower

$0.00

(0.00%)

13:40
12/08/19
12/08
13:40
12/08/19
13:40
Upgrade
China Tower rating change at Deutsche Bank »

China Tower upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

13:37
12/08/19
12/08
13:37
12/08/19
13:37
Recommendations
Principia Biopharma analyst commentary at Stifel »

Principia shares have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DY

Dycom

$50.93

0.495 (0.98%)

12:48
12/08/19
12/08
12:48
12/08/19
12:48
Syndicate
Dycom withdraws senior notes offering due to market conditions »

Dycom Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

IMV

IMV Inc.

$2.92

0.07 (2.46%)

12:30
12/08/19
12/08
12:30
12/08/19
12:30
Hot Stocks
IMV announces updated results from Phase 2 study of DPX-Survivac »

IMV Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KURA

Kura Oncology

$15.67

0.48 (3.16%)

12:27
12/08/19
12/08
12:27
12/08/19
12:27
Hot Stocks
Kura Oncology announces updates for lead drug candidate tipifarnib »

Kura Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PTLA

Portola Pharmaceuticals

$29.22

0.86 (3.03%)

12:24
12/08/19
12/08
12:24
12/08/19
12:24
Hot Stocks
Portola presents interim results from Phase 2a study of cerdulatinib »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

11:25
12/08/19
12/08
11:25
12/08/19
11:25
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

10:49
12/08/19
12/08
10:49
12/08/19
10:49
Hot Stocks
Fate Therapeutics announces vivo preclinical data for FT596 »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

10:04
12/08/19
12/08
10:04
12/08/19
10:04
Hot Stocks
Stoke Therapeutics presents STK-001 preclinical data in Dravet syndrome »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

09:25
12/08/19
12/08
09:25
12/08/19
09:25
Hot Stocks
Autolus announces new data highlighting progress on AUTO3 »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.